Clinical trials: Transmission
HIV Infections
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens.
- Trial name
- PEARLS (NCT00084136)
- Testing
- Atazanavir, Didanosine (enteric-coated), Efavirenz
- Where
- 42 sites in United States, Brazil and 7 more
- Volunteers
- 1,571 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Malaria
A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
Part A -Cohort 1 DSM265 will be administered as a single dose (400 mg). For cohort 1 only, an additional single dose (400 mg) of DSM265 may be given if gametocytemia develops.
- Trial name
- DSMOZ-2 (NCT02573857)
- Testing
- DSM265, OZ439
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Human Immunodeficiency Virus
HIV Non-Occupational Post-Exposure Prophylaxis
The purpose of this study is to see if an anti-HIV medication known as Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir DF) is safe, tolerable and acceptable when taken for 28 days, once a day after a possible, sexual…
- Trial name
- QUAD (NCT01855867)
- Testing
- Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kenneth H. Mayer, MD
Human Papillomavirus (HPV) Infection
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
Cervical cancer is the second most common cancer among women worldwide. Approximately 500 000 new cases are reported each year worldwide, from which 83% occur in developing countries.
- Trial name
- NCT00481767
- Testing
- Cervarix
- Where
- 2 sites in Senegal, Tanzania
- Volunteers
- 676 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
Use of HIV Self-Test Kits to Increase Identification of HIV-Infected Individuals and Their Partners
This study comprises two trials to evaluate the feasibility and cost-effectiveness of HIV self-testing strategies compared to standard of care among clients in outpatient departments (OPD; Aim 1) and the sexual partners of…
- Trial name
- NCT03271307
- Testing
- Optimized PITC, Facility HIVST, Index HIVST
- Where
- Malawi
- Volunteers
- 6,369 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HIV, Sexually Transmitted Infections
Connecting Resources for Urban Sexual Health
The overall goal of the CRUSH project is to enhance and extend a response to the local HIV/AIDS epidemic in Alameda County with a set of innovative, evidence-based interventions across the continuum of HIV prevention and care…
- Trial name
- CRUSH (NCT02183909)
- Testing
- Testing and linkage to care for Y/MSM, Engagement and retention for HIV-positive Y/MSM in care, Engagement and retention for HIV-negative Y/MSM in sexual health services
- Where
- United States
- Volunteers
- 378 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Human Immunodeficiency Virus
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
The purpose of the study is to assess: 1 safety and tolerability of adenovirus serotype 26 (Ad26) prime and Modified Vaccinia Ankara (MVA) boost versus placebo in participants on suppressive antiretroviral therapy (ART) that was…
- Trial name
- NCT02919306
- Testing
- Ad26.Mos.HIV, MVA-Mosaic
- Where
- Thailand
- Volunteers
- 27 people
- Sponsor
- Janssen Vaccines & Prevention B.V.
Endothelial Function, Lipids
Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study
The purpose of this study is to determine the safety and effects of etravirine, an HIV antiretroviral medication, on vascular function.
- Conditions
- Endothelial Function, Lipids, Insulin Resistance, Inflammation
- Trial name
- NCT00871234
- Testing
- Etravirine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Indiana University
Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
Background: Human immunodeficiency virus (HIV)-infected patients have a weakened immune system, and chemotherapy, which is used to treat lymphoma, probably causes further damage to the immune system.
- Trial name
- NCT00006436
- Testing
- Rituximab, Filgrastim, EPOCH
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Breastfeeding
Intergenerational Transmission of Low-calorie Sweeteners Via Breast Milk
This project aims to measure the widely consumed low-calorie sweeteners (LCS) sucralose and acesulfame-potassium, in maternal breast milk and plasma at pre-specified timepoints over 72 hours and in a single sample of infants'…
- Trial name
- NCT05379270
- Testing
- Diet soda
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- George Washington University
Monkeypox, HIV Coinfection
Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV
This data collection study aims to describe and compare the outcomes of Mpox on people living with HIV (PLHIV) and HIV-negative individuals who are on pre-exposure prophylaxis (PrEP).
- Trial name
- MASH1 (NCT05965427)
- Testing
- No intervention
- Where
- 9 sites in France, Poland and 2 more
- Volunteers
- 2,000 people
- Sponsor
- NEAT ID Foundation
Sexually Transmitted Infection, Alcohol Use Complicating the Puerperium
Technology-Based Intervention for Reducing Sexually Transmitted Infections and Substance Use During Pregnancy
This proposed study is to test whether Health Check-up for Expectant Moms (HCEM), a computer-delivered screening and brief intervention (SBI) that simultaneously targets sexually transmitted infection (STI) risk and alcohol/drug…
- Conditions
- Sexually Transmitted Infection, Alcohol Use Complicating the Puerperium, Alcohol Use Complicating Pregnancy, Unspecified Trimester, Drug Use
- Trial name
- NCT03826342
- Testing
- Health Check-up for Expectant Moms, Time, attention, and information-matched control
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Michigan
AIDS, AIDS Vaccines
Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects
The purpose of this study is to investigate a combined set of parameters deemed to impact the quality of CMI analyses in terms of the proportion of viable lymphocytes in antiretroviral therapy-naïve HIV-1 infected subjects.
- Trial name
- NCT01610427
- Testing
- Blood sample collection
- Where
- Belgium
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Acquired Immune Deficiency Syndrome
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
The ideal anti-HIV medications for patients with advanced HIV disease is unknown. There is evidence that anti-HIV regimens that contain protease inhibitors can enhance immune function better than regimens that do not contain…
- Trial name
- NCT00775606
- Testing
- Lopinavir 400 mg/ritonavir 100 mg, Efavirenz
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Rush University Medical Center
HIV Infection
Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)
To evaluate the safety and efficacy of reformulated raltegravir (MK-0518) 1200 mg once daily in combination with TRUVADA™ versus raltegravir 400 mg twice daily in combination with TRUVADA™ in HIV-1 infected, treatment-naive…
- Trial name
- onceMRK (NCT02131233)
- Testing
- Reformulated Raltegravir, Raltegravir, TRUVADA™
- Volunteers
- 802 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV/AIDS
Suubi4Her: Combination Intervention for Adolescent Girls Transitioning Into Adulthood in Uganda
This study examines the impact and cost associated with Suubi4Her, an innovative combination intervention that aims to prevent HIV risk behaviors among 15-17 year-old girls living in communities heavily affected by poverty and…
- Trial name
- NCT03307226
- Testing
- Youth Development Accounts (YDA), YDA + Multiple Family Groups (MFG)
- Where
- 2 sites in Uganda
- Volunteers
- 1,260 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
HIV Infections
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
The purpose of this study is to see if it is effective to give HIV positive patients recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy.
- Trial name
- ESPRIT (NCT00004978)
- Testing
- Recombinant interleukin-2 (rIL-2)
- Where
- 248 sites in United States, Argentina and 23 more
- Volunteers
- 4,150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Disease
Therapy to Elevate CD4 Counts in HIV-1 Disease
For more than 20 years, alpha-1-proteinase inhibitor therapy has been the standard treatment for patients who have inherited alpha-1-proteinase inhibitor deficiency.
- Trial name
- NCT01370018
- Testing
- alpha-1-Proteinase Inhibitor
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Institute for Human Genetics and Biochemistry
HIV Infections
A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.
The primary objective is to establish the pharmacokinetic (PK) profile at steady state of nevirapine XR in HIV infected children from >=3 to <18 years of age.
- Trial name
- NCT00905489
- Testing
- Nevirapine Immediate Release (IR), Nevirapine Extended Release (XR)
- Where
- 10 sites in United States, Botswana and 2 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)
This protocol represents the third in human study of TUTI-16, and is being conducted to gather additional safety and human immunogenicity (anti-HIV-1 Tat titers) data of subcutaneously administered TUTI-16.
- Trial name
- NCT01335191
- Testing
- TUTI-16 (1.0 mg)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Thymon, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.